Market OverviewThe Global Smart Medical Devices Market is valued at USD 90.55 Billion in 2024 and is projected to reach a ...

Users of Abbott’s CGM device can now view data and gain additional insights through Glooko’s diabetes management platform.

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

paired with Abbott’s Freestyle Libre 2 continuous glucose monitor—among people who were not previously meeting their blood sugar goals. The results were presented at the International ...

Abbott's FreeStyle Libre system and new Protality brand highlight ... treatment strategy fails to gain traction. In a more neutral case where Abbott continues steady growth in diagnostics diabetes ...

In most cases, Abbott is one of three or four competitors ... Over the longer time frame, we continue to anticipate top-line strength from FreeStyle Libre, ongoing adoption of the Alinity systems ...

Biosensors are changing how we monitor health, but rapid innovation raises tough questions around privacy, regulation, and ...

HEAL seeks to provide investors exposure to the growing HealthTech industry, which is expected to grow fourfold from $225 ...

Over the past few decades, there has been a steady rise in both the prevalence and the number of cases of diabetes ... countries with Abbott’s FreeStyle Libre 2+ and Dexcom’s G6 CGM sensors ...

The global MRI-Safe CRT devices market is witnessing significant momentum, poised to more than double in size over the next ...